Dr. Mark Bustoros is a physician-scientist whose research focuses on Multiple Myeloma and other Plasma Cell Dyscrasia, including Waldenstrom Macroglobulinemia and Amyloidosis. He is an Assistant Professor at the Department of Hematology and Medical Oncology at Weill Cornell Medicine.
Dr. Bustoros leads the Plasma cell Dyscrasia lab at Weill Cornell Medicine, which focuses on identifying mechanisms of progression in multiple myeloma, either the cell-autonomous or those dependent on the bone marrow niche. His work involves studying genetic and epigenetic alterations that regulate tumor dissemination and the role of the bone marrow niche in disease progression from early precursor stages (MGUS and smoldering myeloma) to active Multiple Myeloma. His lab also studies the mechanisms of therapeutic resistance in relapsed refractory myeloma and identifying new targets and therapeutic approaches that could be effective in specific molecular subtypes of myeloma.

Dr. Bustoros is a member of the American Society of Hematology, the American Association for Cancer Research (AACR), the International Myeloma Society, and the European Hematology Association. He has received multiple awards, such as the Young Investigator Awards from the International Myeloma Society, the AACR- Korean Cancer Association, and the International Workshop of Waldenstrom Macroglobulinemia. He did his post-doctoral training at the Dana-Farber Cancer Institute, where he also became an Instructor of Medicine at Harvard Medical School.